Drugs / CBB 1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05832073 | Apr → Dec 2023 | rabies | Changchun BCHT Biotechnology Co. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06548139 | Jul 2024 → May 2025 overdue | rabies | Changchun BCHT Biotechnology Co. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBB 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548139 ↗ |
| Known as | rabies mAb CBB 1 | “rabies mAb CBB 1 is mainly used for passive immunization of patients bitten or scratched by rabies or other animals carrying rabies virus” NCT05832073 ↗ |
| Modality | Monoclonal antibody | “Natural full human monoclonal antibody CBB 1 injection” NCT05832073 ↗ |
| Route | Intramuscular | “Mode of administration: intramuscular injection of the vastus lateralis muscle.” NCT05832073 ↗ |